Details of the Drug

General Information of Drug (ID: DMJCT6Q)

• Drug Name: CD19 CAR T-cells

Indication

Disease Entry	ICD 11	Status	REF
Acute lymphoblastic leukaemia	2A85	Phase 1	[1]
Non-hodgkin lymphoma	2B33.5	Phase 1	[2]
Recurrent adult burkitt lymphoma	2A85.6	Phase 1	[1]

• Drug Type: CAR T Cell Therapy
• Cross-matching ID: TTD ID: D0B1CU

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-lymphocyte surface antigen B4 (CD19)	TTW640A	CD19_HUMAN	CAR-T-Cell-Therapy	[2]

Molecular Expression Atlas of This Drug

• The Studied Disease: Acute lymphoblastic leukaemia
• ICD Disease Classification: 2A85

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
B-lymphocyte surface antigen B4 (CD19)	DTT	CD19	2.33E-24	-1.06	-1.33

References

• [1] ClinicalTrials.gov (NCT02443831) CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies
• [2] ClinicalTrials.gov (NCT03298828) CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma